1. Augood SJ, Westmore K, McKenna PJ, Emson PC. Co-expression of dopamine transporter mRNA and tyrosine hydroxylase mRNA in ventral mesencephalic neurons. Mol Brain Res 1993;20:328–334.

2. Bartfai T, Iverfeldt K, Fisone G, Serfozo P. Regulation of the release of coexisting neurotransmitters. Annu Rev Pharmacol Toxicol 1988;28:285–310.

3. Bean AJ, Roth RH. Extracellular dopamine and neurotensin in rat prefrontal cortex in vivo: effects of median forebrain bundle stimulation frequency, pattern, and dopamine autoreceptors. J Neurosci 1991;11:2694–2702.

4. Bean AJ, Dagerlind A, Hökfelt T, Dobner PR. Cloning of human neurotensin/neuromedin N genomic sequences and expression in the ventral mesencephalon of schizophrenics and age/sex matched controls. Neuroscience 1992;50:259–268.

5. Bean AJ, During MJ, Deutch AY, Roth RH. The effects of dopamine depletion on striatal neurotensin: biochemical and immunohistochemical studies. J Neurosci 1989;9:4430–4438.

6. Bean AJ, Elde R, Cao YH, et al. Expression of fibroblast growth factors in the substantia nigra of rat, monkey, and human. Proc Natl Acad Sci USA 1991;88:10237–10241.

7. Bean AJ, Zhang X, Hökfelt T. Peptide secretion: what do we know? 8:630–638.

8. Bennett M, Scheller RH. A molecular description of synaptic vesicle membrane trafficking. Annu Rev Neurosci 1994;63:63–100.

9. Bloom SR, Edwards AV, Garrett JR. Effects of stimulating the sympathetic innervation in bursts on submandibular vascular and secretory function in cats. J Physiol 1987;393:91–106.

10. Borowsky B, Mezey E, Hoffman BJ. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 1993;10:851–863.

11. Burgevin M-C, Castel M-N, Quarteronet D, Chevet T, Laduron PM. Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport. Neuroscience 1992;49:627–633.

12. Clark J, Deutch AY, Gallipoli PZ, Amara S. Functional expression and CNS distribution of a b-alanine-sensitive neuronal GABA transporter. Neuron 1992;9:337–348.

13. Dale H. Pharmacology and nerve endings. Proc R Soc Med 1935;28:319–332.

14. Deutch AY, Zahm DS. The current status of neurotensin–dopamine interactions: issues and speculations. Ann NY Acad Sci 1992; 668:232–252.

15. Deutch AY, Holliday J, Roth RH, Chun LLY, Hawrot E. Immunohistochemical localization of a neuronal nicotinic acetylcholine receptor in mammalian brain. Proc Natl Acad Sci USA 1987;84:8697–8701.

16. Distler P. Synaptic connections of dopamine immunoreactive neurons in the antennal lobes of Periplaneta americana. Colocalization with GABA-like immunoreactivity. Histochem 1990;93:401–408.

17. Eccles JC. Chemical transmission and Dale's principle. Prog Brain Res 1986;68:3–13.

18. Elde R, Schalling M, Ceccatelli S, Nakanishi S, Hökfelt T. Localization of neuropeptide receptor mRNA in rat brain: initial observations using probes for neurotensin and substance P receptors. Neurosci Lett 1990;120:134–138.

19. Eberle-Wang K, Mikeladze Z, Chesselet M-F. Expression of 5-HT1c receptor mRNA in the basal ganglia of rats. Soc Neurosci Abstr 1993;19:132.

20. Everitt BJ, Meister B, Hökfelt T, et al. The hypothalamic arcuate nucleus–median eminence complex: immunohistochemistry of transmitters, peptides and DARPP-32 with special reference to coexistence in dopamine neurons. Brain Res Rev 1986;11:97–155.

21. Gall CM, Hendry SHC, Seroogy KB, Jones EG, Haycock JW. Evidence for coexistence of GABA and dopamine in neurons of the rat olfactory bulb. J Comp Neurol 1987;266:307–318.

22. Fritschy J-M, Benke D, Mertens S, Oertel WH, Bach T, Mohler H. Five subtypes of type A gamma-aminobutyric acid receptors identified in neurons by double and triple immunofluorescence staining with subunit-specific antibodies. Proc Natl Acad Sci USA 1992;89:6726–6730.

23. Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic. III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J Neurosci 1987;7:3915.

24. German DC, Liang C-L. Neuroactive peptides in the midbrain dopaminergic neurons that contain calbindin-D28k. Neuroreport 1993; 4:491–494.

25. Gibb WR. Melanin, tyrosine hydroxylase, calbindin, and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283–291.

26. Goldstein M, Deutch AY. The inhibitory action of neuropeptide Y and galanin on 3H-norepinephrine release in the central nervous system: Relation to a proposed hierarchy of neuronal molecular coexistence. In: Mutt V, Fuxe K, Hökfelt T, Lundberg JM, eds. Neuropeptide Y. New York: Raven Press, 1989;153–162.

27. Greenfield SA. A noncholinergic action of acetylcholinesterase (AChE) in the brain: from neuronal secretion to the generation of movement. Cell Mol Neurobiol 1991;11:55–77.

28. Haglund L, Kohler C, Haaparanta T, Goldstein M, Gustafsson J-A. Presence of NADPH-cytochrome P450 reductase in central catecholamine neurons. Nature 1984;307:259–262.

29. Harfstrand A, Fuxe K, Cintra A, et al. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc Natl Acad Sci USA 1986;83:9779–9783.

30. Hattori T, Takada M, Moriizumi, van der Kooy D. Single dopaminergic nigrostriatal neurons form two chemically distinct synaptic types: possible transmitter segregation within neurons. J Comp Neurol 1991;309:391–401.

31. Hökfelt T. Neuropeptides in perspective: the last ten years. Neuron 1991;7:867–879.

32. Hökfelt T, Everitt BJ, Theodorsson-Norheim E, Goldstein M. Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J Comp Neurol 1984;222:543–559.

33. Hökfelt T, Johansson O, Holets V, Meister B, Melander T. Distribution of neuropeptides with special reference to their coexistence with classical transmitters. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;401–416.

34. Hökfelt T, Skirboll L, Rehfeld JF, Goldstein M, Markey K, Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 1980;5:2093–2124.

35. Honda T, Wada E, Dattey JF, Tank SA. Differential gene expression of CCKA and CCKB receptors in the rat brain. Mol Cell Neurosci 1993;4:143–154.

36. Iverfelt K, Serfozo P, Diaz AL, Bartfai T. Differential release of coexisting neurotransmitters: frequency dependence of the efflux of substance P, thyrotrophin releasing hormone, and [3H]-serotonin from tissue slices of rat ventral spinal cord. Acta Physiol Scand 1989;137:63–71.

37. Jan YN, Jan LY. Some features of peptidergic transmission. Prog Brain Res 1983;58:49–59.

38. Kaneko T, Akiyama H, Nagatsu I, Mizuno N. Immunohistochemical demonstration of glutaminase in catecholaminergic and serotonergic neurons of rat brain. Brain Res 1990;507:151–154.

39. Kelley RB. Storage and release of neurotransmitters. Cell 1993; 72:43–53.

40. Kosaka T, Kosaka K, Nagatsu I. Tyrosine hydroxylase-like immunoreactive neurons in the olfactory bulb of the snake, Elaophe quadrivirgata, with special reference to the colocalization of tyrosine hydroxylase- and GABA-like immunoreactivities. Exp Brain Res 1991;87:353–362.

41. Krause JE, Bu JY, Takeda Y, et al. Structure, expression and second messenger-mediated regulation of the human and rat substance P receptors and their genes. Regul Pept 1993;46:59–66.

42. Levoie B, Parent A. Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Neuroreport 1991;2:601–604.

43. Liu Y, Peter D, Roghani A, et al. A cDNA that suppresses MPP + toxicity encodes a vesicular amine transporter. Cell 1992; 70:539–551.

44. Lundberg JM. Peptide and classical transmitter mechanisms in the autonomic nervous system. Arch Int Pharmacodyn Ther 1990;303:9–19.

45. Mansour A, Watson SJ. In: Herz A, ed. Opioids I. Handbook of experimental pharmacology, vol 104. Berlin: Springer-Verlag, 1993;79–106.

46. Martin LJ, Blackstone CD, Levey AI, Huganir RL, Price DL. AMPA glutamate receptor subunits are differentially distributed in rat brain. Neuroscience 1993;53:327–358.

47. Meister B, Elde R. Dopamine transporter mRNA in neurons of the rat hypothalamus. Neuroendocrinology 1993;58:388–395.

48. Meng F, Xie GX, Thompson RC, et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci USA 1993;90:9954–9998.

49. Orazzo C, Pierebone VA, Ceccatelli S, Ternenius L, Hökfelt T. CGRP-like immunoreactivity in A11 dopamine neurons projecting to the spinal cord and a note on CGRP-CCK cross-reactivity. Brain Res 1993;600:39–48.

50. Savasta M, Palacios JM, Mengod G. Regional distribution of the messenger RNA coding for the neuropeptide cholecystokinin in the human brain examined by in situ hybridization. Mol Brain Res 1990;7:91–104.

51. Schalling M, Friberg K, Seroogy K, et al. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Proc Natl Acad Sci USA 1990;87:8427–8431.

52. Schultzberg M, Segura-Aguilar J, Lind C. Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 1988;27:763–776.

53. Seroogy KB, Gall CM. Expression of neurotrophins by midbrain dopaminergic neurons. Exp Neurol 1993;124:119–128.

54. Seroogy K, Tsuruo Y, Hökfelt T, et al. Further analysis of presence of peptides in dopamine neurons. Exp Brain Res 1988;72:523–534.

55. Seroogy KB, Ceccatelli S, Schalling M. A subpopulation of dopaminergic neurons in rat ventral mesencephalon contains both neurotensin and cholecystokinin. Brain Res 1988;455:88–98.

56. Smith S, Augustine GJ. Calcium ions, active zones, and synaptic transmitter release. Trends Neursci 1988;11:458–465.

57. Sossin WS, Sweet-Cordero A, Scheller RH. Dale's hypothesis revisited: different neuropeptides derived from a common prohormone are targeted to different processes. Proc Natl Acad Sci USA 1990;87:4845–4848.

58. Thompson RC, Mansour A, Akil H, Watson SJ. Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron 1993;11:903–913.

59. Verdoorn TA, Draguhn A, Ymer S, Seeburg PH, Sakmann B. Functional properties of recombinant rat GABAA receptors depend upon subunit composition. Neuron 1990;4:919–928.

60. Verhage M, McMahon HT, Ghijsen WE. Differential release of amino acids, neuropeptides, and catecholamines from isolated nerve terminals. Neuron 1991;6:517–524.

61. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 1990;526:303.

62. Wada E, Wada K, Boulter J, et al. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemistry study in the rat. J Comp Neurol 1989;284:314–335.

63. Whim MD, Lloyd PE. Frequency dependent release of peptide co-transmitters from identified cholinergic motor neurons in Aplysia. Proc Natl Acad Sci USA 1989;86:9034–9038.

64. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992;12:1040–1062.

65. Wolfe J, Beaudet A. Neurotensin terminals form synapses primarily with neurons lacking detectable tyrosine hydroxylase immunoreactivity in the rat substantia nigra and ventral tegmental area. J Comp Neurol 1992;321:163–176.